

## IMPORTANT INFORMATION

**NeoFax®**  
October 31, 2014

A review of the NeoFax® CAFFEINE CITRATE monograph has revealed an issue. In the Special Considerations/Preparation section of the document, under the heading Extemporaneous Compounds, an incorrect strength is displaying for both the Injectable Solution and the Oral Solution.

The incorrect strength information is displayed as “10 mg/mL”.

The correct strength information is “20 mg/mL”.

This issue affects all NeoFax products, including the mobile app.

We are investigating the issue and will notify you early next week when the fix will be available. **In the meantime, clinicians should refer to this bulletin and not what is currently displayed in the NeoFax® product concerning Caffeine Citrate Extemporaneous Compounding.**

If you have any further questions, please do not hesitate to contact us:

U.S. and Canada: 1-800-525-9083/ Global: 1-303-486-6444

Dial 3-3 at the voice prompt for Product Support

Email Requests: <http://www.micromedex.com/request>

Thank you,

Truven Health Analytics